TABLE 6.

Clinical trials depicting population characteristics, clinical scenarios and interventions, and prognostic performance of the iBox risk score (62–64).

Study	Trial ID	Design	Clinical scenario	Target population	n	Time post-transplant (y) of risk score evaluation median, IQR	Follow-up time post-transplant (y) median, IQR	Risk score C-stat
CERTITEM (64)	NCT 01079143	Prospective, randomized, open‐label, multicentre trial	Immuno-suppressive drug minimization	Recipients of renal transplants from a living or deceased donor	194	0.94	6.62	0.88
						0.92–0.98	2.82–7.34
RITUX ERAH (63)	EudraCT 2007-003213-13	Prospective, randomized, multicentre, double-blind, placebo-controlled trial	AMR treatment (pre-existing DSA)	Recipients of renal transplants from a living or deceased donor with diagnosis of aAMR	38	0.74	6.63	0.77
						0.53–1.10	4.03–7.69
BORTEJECT (62)	NCT 01873157	Prospective, randomized, placebo-controlled, double-blind, single-center trial	AMR treatment (dnDSA)	Recipients of renal transplants from a living or deceased donor with post-transplant dnDSA detection	44	6.61	7.75	0.94
						4.04–15.41	5.32–16.41

A, acute/active; AMR, antibody-mediated rejection; dn, de novo; DSA, donor-specific antibodies; IQR, interquartile range.